Pulmonary Tuberculosis (TB) charts among the top ten infectious diseases worldwide, as per the World Health Organization (WHO). Although new treatments (anti-tuberculars and combinatorial therapy) are emerging, these treatments come with significant side-effects. Due to the recent COVID 19 pandemic, TB programs all over the world faced major setbacks, which demands revaluation of goals and assessment of milestones set for ‘End TB Strategy’ program devised by the WHO.
This Topic aims to propel clinical as well as basic research in the area of TB treatment, disease management, drug discovery and understanding the metabolic re-modelling of Mycobactrium tuberculosis as a pathogen in response to various drugs. We aspire to reach new heights in diagnosis, treatment and control of the tuberculosis epidemic, worldwide.
Potential subtopics for exploration include, but are not limited to:
• Investigations of pathogenesis and determinants of TB
• Comprehensive investigations into treatment/ drug discovery (and/or development) against pulmonary TB.
• Advancements in vaccines, diagnostic methodologies for TB.
• Innovative therapeutic approaches for patients with MDR/XDR TB.
• Explorations into the molecular and genetic underpinnings of mycobacteria n context with metabolic responses to various drugs/lead molecules.
Keywords:
Tuberculosis, Mycobacterium tuberculosis, Drug Discovery, Clinical Trials, Treatment, Disease management, Drug Resistance
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Pulmonary Tuberculosis (TB) charts among the top ten infectious diseases worldwide, as per the World Health Organization (WHO). Although new treatments (anti-tuberculars and combinatorial therapy) are emerging, these treatments come with significant side-effects. Due to the recent COVID 19 pandemic, TB programs all over the world faced major setbacks, which demands revaluation of goals and assessment of milestones set for ‘End TB Strategy’ program devised by the WHO.
This Topic aims to propel clinical as well as basic research in the area of TB treatment, disease management, drug discovery and understanding the metabolic re-modelling of Mycobactrium tuberculosis as a pathogen in response to various drugs. We aspire to reach new heights in diagnosis, treatment and control of the tuberculosis epidemic, worldwide.
Potential subtopics for exploration include, but are not limited to:
• Investigations of pathogenesis and determinants of TB
• Comprehensive investigations into treatment/ drug discovery (and/or development) against pulmonary TB.
• Advancements in vaccines, diagnostic methodologies for TB.
• Innovative therapeutic approaches for patients with MDR/XDR TB.
• Explorations into the molecular and genetic underpinnings of mycobacteria n context with metabolic responses to various drugs/lead molecules.
Keywords:
Tuberculosis, Mycobacterium tuberculosis, Drug Discovery, Clinical Trials, Treatment, Disease management, Drug Resistance
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.